Plus Therapeutics CEO: Lead candidate REYOBIQ demonstrates strong safety and efficacy in early trials
Plus Therapeutics (NASDAQ: PSTV) is a pharmaceutical company engaged in the development of targeted radiotherapeutics for difficult-to-treat cancers. Currently, it is advancing a pipeline of product candidates with lead programs in leptomeningeal metastases and recurrent glioblastoma. In an email conversation with AlphaStreet, Dr. Marc Hedrick, chief executive officer of Plus Therapeutics, provided insights into the … Read more
